title: Update on the use of magnesium sulphate for fetal neuroprotection in preterm birth.
abstract: The administration of magnesium sulphate to mothers at risk for preterm birth for fetal neuroprotection has demonstrated to reduce the risk of cerebral palsy and gross motor dysfunction by 30-40%. Although there is controversy regarding the regimen of administration of magnesium sulphate, the gestational age limit, the extent of its potential benefit or even if it provides any benefit, current evidence is enough to support the use of magnesium sulphate in women at imminent risk for preterm delivery before 32 weeks of gestation. The objective of this study is to describe available evidence and current recommendations regarding neuroprotection with magnesium sulphate.
authors.affiliation: Servicio de Obstetricia y Unidad de Medicina Fetal, Hospital Italiano, Buenos Aires.
authors.forename: César Hernán
authors.initials: CH
authors.lastname: Meller
authors.affiliation: Servicio de Obstetricia y Unidad de Medicina Fetal, Hospital Italiano, Buenos Aires.
authors.forename: Gustavo
authors.initials: G
authors.lastname: Izbizky
authors.affiliation: Servicio de Obstetricia y Unidad de Medicina Fetal, Hospital Italiano, Buenos Aires.
authors.forename: Lucas
authors.initials: L
authors.lastname: Otaño
mesh_terms: D001927:Brain Diseases / Q000517:prevention & control*; D005315:Fetal Diseases / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D047928:Premature Birth
chemical_list: D008278:Magnesium Sulfate